Il27 Mouse Gene Knockout Kit (CRISPR)

CAT#: KN508277

Il27 - KN2.0, Mouse gene knockout kit via CRISPR, non-homology mediated.



KN2.0 knockout kit validation

  See Other Versions

USD 1,657.00

2 Weeks*

Size
    • 1 kit

Product Images

Frequently bought together (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

USD 450.00


Rat monoclonal Mouse IL-27/P28 antibody
    • 100 ug

USD 780.00


Il27 (Myc-DDK-tagged) - Mouse interleukin 27 (Il27)
    • 10 ug

USD 450.00

Other products for "Il27"

Specifications

Product Data
Format 2 gRNA vectors, 1 linear donor
Donor DNA EF1a-GFP-P2A-Puro
Symbol Il27
Locus ID 246779
Components

KN508277G1, Il27 gRNA vector 1 in pCas-Guide CRISPR vector

KN508277G2, Il27 gRNA vector 2 in pCas-Guide CRISPR vector

KN508277D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA CATCGCCCAC AGTCCCCGAG AAGTTGGGGG GAGGGGTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG CGGGGTAAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCGC CTTTTTCCCG AGGGTGGGGG AGAACCGTAT ATAAGTGCAG TAGTCGCCGT GAACGTTCTT TTTCGCAACG GGTTTGCCGC CAGAACACAG GTAAGTGCCG TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTTCGAG GCCTTGCGCT TAAGGAGCCC CTTCGCCTCG TGCTTGAGTT GAGGCCTGGC CTGGGCGCTG GGGCCGCCGC GTGCGAATCT GGTGGCACCT TCGCGCCTGT CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTTT GATGACCTGC TGCGACGCTT TTTTTCTGGC AAGATAGTCT TGTAAATGCG GGCCAAGATC TGCACACTGG TATTTCGGTT TTTGGGGCCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCGAGGCGG GGCCTGCGAG CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC GCCGTGTATC GCCCCGCCCT GGGCGGCAAG GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAAGATGG CCGCTTCCCG GCCCTGCTGC AGGGAGCTCA AAATGGAGGA CGCGGCGCTC GGGAGAGCGG GCGGGTGAGT CACCCACACA AAGGAAAAGG GCCTTTCCGT CCTCAGCCGT CGCTTCATGT GACTCCACGG AGTACCGGGC GCCGTCCAGG CACCTCGATT AGTTCTCGAG CTTTTGGAGT ACGTCGTCTT TAGGTTGGGG GGAGGGGTTT TATGCGATGG AGTTTCCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAC TTGATGTAAT TCTCCTTGGA ATTTGCCCTT TTTGAGTTTG GATCTTGGTT CATTCTCAAG CCTCAGACAG TGGTTCAAAG TTTTTTTCTT CCATTTCAGG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCGAGC AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCCTACC TGCTGAGCCA CGTGATGGGC TACGGCTTCT ACCACTTCGG CACCTACCCC AGCGGCTACG AGAACCCCTT CCTGCACGCC ATCAACAACG GCGGCTACAC CAACACCCGC ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT TCAGCTACCG CTACGAGGCC GGCCGCGTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCCGAGGA CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGGCGAT AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTACTACAGC TCCGTGGTGG ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCCA TGTTCGCCTT CCGCCGCGTG GAGGAGGATC ACAGCAACAC CGAGCTGGGC ATCGTGGAGT ACCAGCACGC CTTCAAGACC CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACTTCAG CCTGCTGAAG CAGGCTGGAG ACGTGGAGGA GAACCCTGGA CCTATGACCG AGTACAAGCC CACGGTGCGC CTCGCCACCC GCGACGACGT CCCCAGGGCC GTACGCACCC TCGCCGCCGC GTTCGCCGAC TACCCCGCCA CGCGCCACAC CGTCGATCCG GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC GACATCGGCA AGGTGTGGGT CGCGGACGAC GGCGCCGCGG TGGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGGC GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCCCGGC TGGCCGCGCA GCAACAGATG GAAGGCCTCC TGGCGCCGCA CCGGCCCAAG GAGCCCGCGT GGTTCCTGGC CACCGTCGGC GTCTCGCCCG ACCACCAGGG CAAGGGTCTG GGCAGCGCCG TCGTGCTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGGT GCCCGCCTTC CTGGAGACCT CCGCGCCCCG CAACCTCCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC GCCGACGTCG AGGTGCCCGA AGGACCGCGC ACCTGGTGCA TGACCCGCAA GCCCGGTGCC TGAAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTC ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_145636
UniProt ID Q8K3I6
Synonyms IL-27; IL-27p28; Il30; p28
Summary Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9.[UniProtKB/Swiss-Prot Function]

Other Versions

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.